3
|
Tang Y, Jia Y, Fan L, Liu H, Zhou Y, Wang M, Liu Y, Zhu J, Pang W, Zhou J. MFN2 Prevents Neointimal Hyperplasia in Vein Grafts via Destabilizing PFK1. Circ Res 2022; 130:e26-e43. [PMID: 35450439 DOI: 10.1161/circresaha.122.320846] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Mechanical forces play crucial roles in neointimal hyperplasia after vein grafting; yet, our understanding of their influences on vascular smooth muscle cell (VSMC) activation remains rudimentary. METHODS A cuff mouse model was used to study vein graft hyperplasia. Fifteen percent to 1 Hz uniaxial cyclic stretch (arterial strain), 5% to 1 Hz uniaxial cyclic stretch or a static condition (venous strain) were applied to the cultured VSMCs. Metabolomics analysis, cell proliferation and migration assays, immunoblotting, co-immunoprecipitation, mutagenesis, pull-down and surface plasmon resonance assays were employed to elucidate the potential molecular mechanisms. RESULTS RNA-sequencing in vein grafts and the controls identified changes in metabolic pathways and downregulation of mitochondrial protein MFN2 (mitofusin 2) in the vein grafts. Exposure of VSMCs to 15% stretch resulted in MFN2 downregulation, mitochondrial fragmentation, metabolic shift from mitochondrial oxidative phosphorylation to glycolysis, and cell proliferation and migration, as compared with that to a static condition or 5% stretch. Metabolomics analysis indicated an increased generation of fructose 1,6-bisphosphate, an intermediate in the glycolytic pathway converted by PFK1 (phosphofructokinase 1) from fructose-6-phosphate, in cells exposed to 15% stretch. Mechanistic study revealed that MFN2 physically interacts through its C-terminus with PFK1. MFN2 knockdown or exposure of cells to 15% stretch promoted stabilization of PFK1, likely through interfering the association between PFK1 and the E3 ubiquitin ligase TRIM21 (E3 ubiquitin ligase tripartite motif [TRIM]-containing protein 21), thus, decreasing the ubiquitin-protease-dependent PFK1 degradation. In addition, study of mechanotransduction utilizing pharmaceutical inhibition indicated that the MFN2 downregulation by 15% stretch was dependent on inactivation of the SP1 (specificity protein 1) and activation of the JNK (c-Jun N-terminal kinase) and ROCK (Rho-associated protein kinase). Adenovirus-mediated MFN2 overexpression or pharmaceutical inhibition of PFK1 suppressed the 15% stretch-induced VSMC proliferation and migration and alleviated neointimal hyperplasia in vein grafts. CONCLUSIONS MFN2 is a mechanoresponsive protein that interacts with PFK1 to mediate PFK1 degradation and therefore suppresses glycolysis in VSMCs.
Collapse
Affiliation(s)
- Yuanjun Tang
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,(Hemorheology Center, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China (Y.T., Y.J., L.F., H.L., Y.Z., Y.L., J. Zhu, J. Zhou).,National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides (Y.T., L.F., H.L., Y.L., J. Zhu, J. Zhou).,Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, China (Y.T., L.F., H.L., Y.L., J. Zhu, J. Zhou)
| | - Yiting Jia
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,(Hemorheology Center, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China (Y.T., Y.J., L.F., H.L., Y.Z., Y.L., J. Zhu, J. Zhou)
| | - Linwei Fan
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,(Hemorheology Center, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China (Y.T., Y.J., L.F., H.L., Y.Z., Y.L., J. Zhu, J. Zhou).,National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides (Y.T., L.F., H.L., Y.L., J. Zhu, J. Zhou).,Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, China (Y.T., L.F., H.L., Y.L., J. Zhu, J. Zhou)
| | - Han Liu
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,(Hemorheology Center, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China (Y.T., Y.J., L.F., H.L., Y.Z., Y.L., J. Zhu, J. Zhou).,National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides (Y.T., L.F., H.L., Y.L., J. Zhu, J. Zhou).,Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, China (Y.T., L.F., H.L., Y.L., J. Zhu, J. Zhou)
| | - Yuan Zhou
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China (Y.T., Y.J., L.F., H.L., Y.Z., Y.L., J. Zhu, J. Zhou).,Department of Biomedical Informatics, School of Basic Medical Sciences, Peking University, Beijing, China (Y.Z.)
| | - Miao Wang
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. (M.W.).,Clinical Pharmacology Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. (M.W.)
| | - Yuefeng Liu
- (Hemorheology Center, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China (Y.T., Y.J., L.F., H.L., Y.Z., Y.L., J. Zhu, J. Zhou).,National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides (Y.T., L.F., H.L., Y.L., J. Zhu, J. Zhou).,Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, China (Y.T., L.F., H.L., Y.L., J. Zhu, J. Zhou)
| | - Juanjuan Zhu
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,(Hemorheology Center, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China (Y.T., Y.J., L.F., H.L., Y.Z., Y.L., J. Zhu, J. Zhou).,National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides (Y.T., L.F., H.L., Y.L., J. Zhu, J. Zhou).,Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, China (Y.T., L.F., H.L., Y.L., J. Zhu, J. Zhou)
| | - Wei Pang
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,(Hemorheology Center, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.)
| | - Jing Zhou
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,(Hemorheology Center, School of Basic Medical Sciences, Peking University, Beijing, China. (Y.T., Y.J., L.F., H.L., Y.L., J.Z., W.P., J.Z.).,Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China (Y.T., Y.J., L.F., H.L., Y.Z., Y.L., J. Zhu, J. Zhou).,National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides (Y.T., L.F., H.L., Y.L., J. Zhu, J. Zhou).,Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University, China (Y.T., L.F., H.L., Y.L., J. Zhu, J. Zhou)
| |
Collapse
|
6
|
Ren W, Liang L, Li Y, Wei FY, Mu N, Zhang L, He W, Cao Y, Xiong D, Li H. Upregulation of miR‑423 improves autologous vein graft restenosis via targeting ADAMTS‑7. Int J Mol Med 2020; 45:532-542. [PMID: 31894258 PMCID: PMC6984782 DOI: 10.3892/ijmm.2019.4419] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Accepted: 10/31/2019] [Indexed: 12/20/2022] Open
Abstract
Coronary artery bypass graft (CABG) is one of the primary methods of treating coronary heart disease (CHD); however, vein graft restenosis is a major limiting factor of the effectiveness of CABG. Emerging evidence has indicated that miR‑423 is associated with vascular diseases. Additionally, upregulation of a disintegrin and metalloproteinase with thrombospondin motifs‑7 (ADAMTS‑7) contributes to neointima formation by promoting the proliferation and migration of vascular smooth muscle cells and inhibiting the proliferation and migration of endothelial cells. The aim of the present study was to examine the effects of miR‑423 target, ADAMTS‑7, on regulating vein graft disease and identify novel biomarkers for use in therapy of vein graft failure (VGF). Aberrant expression of miR‑423 in plasma of patients with CHD prior to and following CABG confirms that miR‑423 may be a suitable target for preventing VGF. Furthermore, a dual‑luciferase reporter gene assay indicated that miR‑423 directly interacted with ADAMTS‑7 and suppressed its expression. Ectopic expression of miR‑423 suppressed ADAMTS‑7, resulting in decreased proliferation and migration rates of human umbilical vein smooth muscle cells by targeting ADAMTS‑7, but resulted in increased proliferation and migration of human umbilical vein endothelial cells in vitro. Overexpression of miR‑423 also enhanced re‑endothelialization and decreased neointimal formation in a rat vein graft model. In conclusion, the results of the present study demonstrated that the miR‑423/ADAMTS‑7 axis may possess potential clinical value for the prevention and treatment of restenosis in patients with CHD following CABG.
Collapse
Affiliation(s)
- Wenjun Ren
- Department of Cardiovascular Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650000, P.R. China
| | - Liwen Liang
- Department of Cardiology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650000, P.R. China
| | - Yongwu Li
- Department of Cardiovascular Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650000, P.R. China
| | - Fei-Yu Wei
- Department of Cardiology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650000, P.R. China
| | - Ninghui Mu
- Department of Geriatrics/General Medical Science, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650000, P.R. China
| | - Libin Zhang
- Department of Thoracic Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650000, P.R. China
| | - Wei He
- Department of Medical Services, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650000, P.R. China
| | - Yu Cao
- Department of Cardiovascular Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650000, P.R. China
| | - Da Xiong
- Department of Cardiovascular Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650000, P.R. China
| | - Hongrong Li
- Department of Cardiovascular Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650000, P.R. China
| |
Collapse
|